65,437 trials
Cervical Intraepithelial Neoplasia Grade 2/3 · High-risk HPV (Any Strain)
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants
Accuracy of Respiration Rate Measurement
Primary: Respiration Rate Comparability — 0.4 breaths per minute
Cholera
Primary: % of Participants With Moderate to Severe Diarrhea — 5.7; 59.1 percentage of participants
Depression · Parkinson's Disease
Primary: Hamilton Depression Rating Scale — 16.46; 21.37; 16.35; 20.70 score on a scale
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms of the Left Arm (MVA/HIV62B or Placebo) — 0; 0; 0; 0 Participants
Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 1020; 1100 ng/mL
Substance Use Disorders · Depression · Anxiety
Primary: Acceptability of Adding UP Group Intervention to TAU — 28.0 units on a scale
Relapsed or Refractory Multiple Myeloma
Primary: Objective Response Rate (RR) — 11.3 Percentage of Participants — p=0.419
Acne Vulgaris
Primary: Absolute Change in Mean Lesion Counts at Week 12 — -24.6; -16.6; -16.7; -13.4 lesion counts
Hematological Malignancies
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 58; 27; 81; 95 Participants
Pain, Postoperative
Primary: Effects of Lavender Oil on Postoperative Pain Through Pain Scores — 0.5; 0.9; 3.5; 3.1 score on a scale — p=0.05
Body Fat Disorder
Primary: Percentage of Arms With Correct Identification of Baseline Versus 12-week Treatment Images of the Upper Arms by at Least Two Out of Three Blinded, Independent Reviewers…
Coronary Artery Disease
Primary: Primary Efficacy Endpoint (Powered): Post-PCI Median Minimum Stent Area (MSA) — 5.79; 5.89; 5.49 mm^2
Pulmonary Hypertension
Primary: Pulmonary Vascular Resistance (PVR) Ratio of Week 12 to Baseline — 0.585; 0.757 Ratio — p=0.0158
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months